Splenic imaging with ultrasmall superparamagnetic iron oxide ferumoxtran-10 (AMI-7227): preliminary observations.

@article{citeulike:1249628, abstract = {PURPOSE: Ferumoxtran-10 (ultrasmall superparamagnetic iron oxide; Combidex, AMI-7227) is a long-circulating MR contrast agent with reticuloendothelial uptake known to enhance tissue T1 and T2 relaxation rates. The purpose of this study was to assess the effect of ferumoxtran-10-enhanced MRI in evaluating focal splenic lesions. METHOD: Eighteen patients underwent MR evaluation of the spleen. Two of these patients with exophytic normal splenic tissue (splenules) and 13 of these patients with 24 focal splenic lesions (7 cysts, 2 hemangiomas, 7 metastases, 1 infarct, 7 lymphoma) were assessed by T1-weighted gradient echo and T2-weighted fast SE MRI following intravenous administration of ferumoxtran-10 (1.1 mg of Fe/kg). Qualitative analysis involving improved lesion detection and/or characterization, additional information from postcontrast images affecting staging, and patient management was performed. Quantitative measurements of lesion-to-spleen contrast-to-noise ratio were also performed. RESULTS: Additional information was provided by ferumoxtran-10-enhanced images in 15 of 18 patients. In 8 of 15 (53\%) patients, improved lesion detection (i.e., number of lesions) was obtained on contrast-enhanced images. Improved lesion visualization (i.e., conspicuity) was noted in 11 of 15 (73\%) of patients. In 10 of 15 (67\%) patients, postcontrast imaging provided additional information leading to lesion characterization. Staging of disease and patient management were affected in 5 of 15 (33\%) and 6 of 15 (40\%) patients, respectively. CONCLUSION: Ferumoxtran-10 is a promising contrast agent for the evaluation of focal splenic lesions.}, address = {Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA. mharisinghani@partners.org}, author = {Harisinghani, M. G. and Saini, S. and Weissleder, R. and Rubin, D. and deLange, E. and Harms, S. and Weinreb, J. and Small, W. and Sukerkar, A. and Brown, J. J. and Zelch, J. and Lucas, M. and Morris, M. and Hahn, P. F. }, citeulike-article-id = {1249628}, issn = {0363-8715}, journal = {J Comput Assist Tomogr}, keywords = {mri, sinerem, spleen, uspio}, number = {5}, pages = {770--776}, posted-at = {2007-04-25 08:37:31}, priority = {4}, title = {Splenic imaging with ultrasmall superparamagnetic iron oxide ferumoxtran-10 (AMI-7227): preliminary observations.}, url = {http://view.ncbi.nlm.nih.gov/pubmed/11584239}, volume = {25}, year = {2001} }

TY - JOUR ID - citeulike:1249628 L3 - citeulike-article-id:1249628 TI - Splenic imaging with ultrasmall superparamagnetic iron oxide ferumoxtran-10 (AMI-7227): preliminary observations. JF - J Comput Assist Tomogr VL - 25 IS - 5 SP - 770 EP - 776 AD - Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA. mharisinghani@partners.org SN - 0363-8715 N2 - PURPOSE: Ferumoxtran-10 (ultrasmall superparamagnetic iron oxide; Combidex, AMI-7227) is a long-circulating MR contrast agent with reticuloendothelial uptake known to enhance tissue T1 and T2 relaxation rates. The purpose of this study was to assess the effect of ferumoxtran-10-enhanced MRI in evaluating focal splenic lesions. METHOD: Eighteen patients underwent MR evaluation of the spleen. Two of these patients with exophytic normal splenic tissue (splenules) and 13 of these patients with 24 focal splenic lesions (7 cysts, 2 hemangiomas, 7 metastases, 1 infarct, 7 lymphoma) were assessed by T1-weighted gradient echo and T2-weighted fast SE MRI following intravenous administration of ferumoxtran-10 (1.1 mg of Fe/kg). Qualitative analysis involving improved lesion detection and/or characterization, additional information from postcontrast images affecting staging, and patient management was performed. Quantitative measurements of lesion-to-spleen contrast-to-noise ratio were also performed. RESULTS: Additional information was provided by ferumoxtran-10-enhanced images in 15 of 18 patients. In 8 of 15 (53%) patients, improved lesion detection (i.e., number of lesions) was obtained on contrast-enhanced images. Improved lesion visualization (i.e., conspicuity) was noted in 11 of 15 (73%) of patients. In 10 of 15 (67%) patients, postcontrast imaging provided additional information leading to lesion characterization. Staging of disease and patient management were affected in 5 of 15 (33%) and 6 of 15 (40%) patients, respectively. CONCLUSION: Ferumoxtran-10 is a promising contrast agent for the evaluation of focal splenic lesions. KW - mri KW - sinerem KW - spleen KW - uspio AU - Harisinghani, MG AU - Saini, S AU - Weissleder, R AU - Rubin, D AU - deLange, E AU - Harms, S AU - Weinreb, J AU - Small, W AU - Sukerkar, A AU - Brown, JJ AU - Zelch, J AU - Lucas, M AU - Morris, M AU - Hahn, PF PY - 2001///t UR - http://view.ncbi.nlm.nih.gov/pubmed/11584239 ER -